Sona Discontinues Clinical Trial for COVID-19 Rapid Saliva Test Sona Nanotech Approved for Funding Support to Develop a Bovine Tuberculosis Rapid Test Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test Sona Secures Clinical Trial Authorization and Hospital Partner Sona Establishes an At-The-Market Common Share Offering Sona Announces Filing of Preliminary Short Form Base Shelf Prospectus Pomerantz Law Firm Announces the Filing of a Class Action against Sona Nanotech Inc. and Certain Officers - SNANF Pomerantz Law Firm Announces the Filing of a Class Action against Sona Nanotech Inc. and Certain Officers - SNANF ROSEN, A TOP RANKED LAW FIRM, Reminds Sona Nanotech Inc. Investors of Important February 16 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $100K to Contact Firm - SNANF Pomerantz Law Firm Announces the Filing of a Class Action against Sona Nanotech Inc. and Certain Officers - SNANF SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sona Nanotech Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Sona Nanotech Receives CE Mark Approval for its Rapid COVID-19 Antigen Test SNANF INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit has been Filed Against Sona Nanotech Inc. SNANF Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Sona Nanotech Inc. Shareholders of Class Action and Lead Plaintiff Deadline: February 16, 2021 EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Sona Nanotech Inc. - SNANF